# Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

> **NCT03468153** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

## Key facts

- **NCT ID:** NCT03468153
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-01
- **Primary completion:** 2019-01-01
- **Final completion:** 2020-01-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2018-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03468153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03468153, "Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03468153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*